Flazin as a Promising Nrf2 Pathway Activator

被引:19
|
作者
Fuda, Hirotoshi [1 ]
Miyanaga, Satoshi [1 ]
Furukawa, Takayuki [1 ]
Umetsu, Satomi [1 ]
Joko, Sae [1 ]
Roan, Yuning [1 ]
Suzuki, Hirotaka [1 ]
Hui, Shu-Ping [1 ]
Watanabe, Mitsugu [2 ]
Chiba, Hitoshi [3 ]
机构
[1] Hokkaido Univ, Fac Hlth Sci, Sapporo, Hokkaido 0600812, Japan
[2] Watanabe Oyster Lab Co Ltd, 490-3 Shimoongata Cho, Hachioji, Tokyo 1900154, Japan
[3] Sapporo Univ Hlth Sci, Dept Nutr, Higashi Ku, Nakanuma Nishi 4-2-1-15, Sapporo, Hokkaido 0070894, Japan
关键词
Keap1; Nrf2; hepatocyte; phase II enzyme; flazin; ORAC; MAILLARD REACTION-PRODUCTS; CULTURED HUMAN HEPATOCYTES; OYSTER CRASSOSTREA-GIGAS; OXIDATIVE STRESS; PHENOLIC ANTIOXIDANT; SOY-SAUCE; CELLS; CARCINOGENESIS; INDUCERS; METHYL;
D O I
10.1021/acs.jafc.9b04600
中图分类号
S [农业科学];
学科分类号
09 ;
摘要
Flazin is a beta-carboline-derived alkaloid found in Japanese fermented foods. Here, the potential of flazin as an antioxidant food was studied with particular reference to its effect on the Kelch-like ECH-associated protein 1 (Keap1)-nuclear factor erythroid 2-related factor 2 (Nrf2) system in human hepatocytes (C3A). Flazin and flazin analogues including the decarboxylated derivative perlolyrine were chemically synthesized and compared with each other and with chlorogenic acid and curcumin. Among these compounds, flazin showed the lowest cytotoxicity (IC50 < 500 mu M) and the highest capacity to activate the Keap1-Nrf2 system. It provided the largest (>3-fold of the control) cytoprotection ability against a pro-oxidant, although its radical absorbance capacity was relatively low. Flazin increased the expressions of Nrf2-dependent phase II enzyme genes and their products (NQO1, GSTP, and GSH proteins). The strong cytoprotection ability of flazin associated with low log P (0-3) is shared by sulforaphane and 3,5-dihydroxy-4-methoxybenzyl alcohol, suggesting the potential value of flazin and flazin-rich foods for the prevention of oxidation-related health disorders.
引用
收藏
页码:12844 / 12853
页数:10
相关论文
共 50 条
  • [1] Targeting the NRF2 pathway: A promising approach for corneal endothelial dysfunction
    Ward, Keith W.
    CURRENT OPINION IN PHARMACOLOGY, 2024, 74
  • [2] Nrf2 activator for the treatment of kidney diseases
    Yamawaki, Kengo
    Kanda, Hironori
    Shimazaki, Ryutaro
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2018, 360 : 30 - 37
  • [3] The Nrf2/ARE Pathway: A Promising Target to Counteract Mitochondrial Dysfunction in Parkinson's Disease
    Tufekci, Kemal Ugur
    Bayin, Ezgi Civi
    Genc, Sermin
    Genc, Kursad
    PARKINSONS DISEASE, 2011, 2011
  • [4] The Nrf2 Pathway in Liver Diseases
    Zhou, Jiaming
    Zheng, Qiuxian
    Chen, Zhi
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [5] Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia
    Profeta, Victoria
    McIntyre, Kellie
    Wells, McKenzie
    Park, Courtney
    Lynch, David R.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023, 32 (01) : 5 - 16
  • [6] Magnolia bark extract is a potent Nrf2 activator
    Rajgopal, A.
    Missler, S. R.
    Roloff, S. J.
    Scholten, J. D.
    PLANTA MEDICA, 2015, 81 (11) : 945 - 945
  • [7] Systems biology reveals anatabine to be an NRF2 activator
    Messinis, Dimitris E.
    Poussin, Carine
    Latino, Diogo A. R. S.
    Eb-Levadoux, Yvan
    Dulize, Remi
    Peric, Dariusz
    Guedj, Emmanuel
    Titz, Bjoern
    Ivanov, Nikolai V.
    Peitsch, Manuel C.
    Hoeng, Julia
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [8] Microparticulate/nanoparticulate powders of a novel Nrf2 activator and an aerosol performance enhancer for pulmonary delivery targeting the lung Nrf2/Keap-1 pathway
    Muralidharan, Priya
    Hayes, Don, Jr.
    Black, Stephen M.
    Mansour, Heidi M.
    MOLECULAR SYSTEMS DESIGN & ENGINEERING, 2016, 1 (01): : 48 - 65
  • [9] Nrf2: a promising trove for diabetic wound healing
    Jindam, Amruta
    Yerra, Veera Ganesh
    Kumar, Ashutosh
    ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (23)
  • [10] Chemopreventive promise of targeting the Nrf2 pathway
    Yates, Melinda S.
    Kensler, Thomas W.
    DRUG NEWS & PERSPECTIVES, 2007, 20 (02) : 109 - 117